# RARE catalysts: Ultragenyx Pharmaceutical Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rare/catalysts

> Ultragenyx Pharmaceutical Inc. (RARE) has 10 upcoming catalysts. The next is the setrusumab primary completion, January 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Ultragenyx Pharmaceutical Inc. |
| Ticker | RARE (Nasdaq) |
| SEC CIK | 1515673 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rare |

## Cash runway

Cash $401.0M as of 2026-09-30; quarterly burn $43.0M; about 28.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-445718).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2024 | [Pariglasgene brecaparvovec topline data readout](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE | aged eight years and older | completed, positive | "In May 2024, we announced positive topline results from our Phase 3 GlucoGene study for the treatment of patients aged eight years and older." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1515673/000095017025023312/rare-20241231.htm)) |
| Dec 2024 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA submission](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome type A | completed | "In December 2024, Ultragenyx submitted a BLA to the U.S. Food and Drug Administration for UX111 supported by the available data, including from the ongoing pivotal Transpher A study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-ex99_1.htm)) |
| December 19, 2024 | [Apazunersen trial start](https://sec-api.dev/pdufa/apazunersen) | RARE |  | completed | "On December 19, 2024, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Company's pivotal Phase 3 Aspire study (NCT06617429) evaluating the efficacy and safety of GTX-102, its investigational antisense oligonucleotide ("ASO") for Angelman syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000095017024138467/rare-20241219.htm)) |
| Feb 2025 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA acceptance](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed | "In February 2025, the FDA accepted for review the BLA seeking accelerated approval for UX111." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| February 13, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025019854/rare-ex99_1.htm)) |
| mid-2025 | [Setrusumab interim data readout](https://sec-api.dev/pdufa/setrusumab) | RARE |  | scheduled | ""Patients in the UX143 Phase 3 Orbit and Cosmic studies have now been on therapy for at least 12 months and will support the interim analyses in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| May 6, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| Jul 2025 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA submission](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed | "The resubmitted BLA includes comprehensive responses to chemistry, manufacturing, and controls (CMC)-related observations outlined in a Complete Response Letter (the "CRL") issued in July 2025, as well as additional long-term clinical data from current patients as requested by the Agency in the CRL." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526030590/rare-20260130.htm)) |
| July 7, 2025 | [FAYUVI (rebisufligene etisparvovec) complete response letter (CRL)](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/07/2025 for BL 125845 to Ultragenyx Pharmaceutical Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125845_20250707.pdf%22)) |
| August 5, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-ex99_1.htm)) |
| August 18, 2025 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| Q4 2025 | [Pariglasgene brecaparvovec NDA/BLA submission](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE |  | scheduled | "DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa): BLA submission expected in the fourth quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-ex99_1.htm)) |
| October 20, 2025 | [Setrusumab primary completion](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | completed | "NCT05125809 (Setrusumab vs Placebo for Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125809)) |
| October 23, 2025 | [Bisphosphonate primary completion](https://sec-api.dev/pdufa/bisphosphonate) | RARE | Osteogenesis Imperfecta | completed | "NCT05768854 (Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-23 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05768854)) |
| October 30, 2025 | [Apazunersen trial start](https://sec-api.dev/pdufa/apazunersen) | RARE |  | completed | "On October 30, 2025, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Aurora study (NCT07157254) evaluating the efficacy and safety of GTX-102 (apazunersen), an investigational antisense oligonucleotide ("ASO") for Angelman syndrome ("AS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312525257538/rare-20251030.htm)) |
| November 3, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-ex99_1.htm)) |
| early 2026 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA submission](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | scheduled | "UX111 AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA): expect to resubmit Biologics License Application (BLA) early in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312525264707/rare-ex99_1.htm)) |
| January 12, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "The Company expects to issue financial guidance for fiscal year 2026, including details on previously announced planned expense reductions, and full financial results for the fourth quarter and fiscal year 2025, in February 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-ex99_1.htm)) |
| January 30, 2026 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA submission](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome type A | completed | "On January 30, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that that it has resubmitted its Biologics License Application ("BLA") seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA) to the U.S. Food and Drug Administration (the "FDA" or the "Agency")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526030590/rare-20260130.htm)) |
| February 12, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-ex99_1.htm)) |
| February 12, 2026 | [Ultragenyx Pharmaceutical Inc. NDA/BLA submission](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Earlier today the company received an Incomplete Response Letter (IRL) regarding its resubmitted BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-ex99_1.htm)) |
| February 23, 2026 | [Pariglasgene brecaparvovec NDA/BLA acceptance](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE | Glycogen Storage Disease Type Ia | completed | "On February 23, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Biologics License Application (the "BLA") seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm)) |
| April 2, 2026 | [FAYUVI (rebisufligene etisparvovec) NDA/BLA acceptance](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome Type A | completed | "On April 2, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the Company's resubmitted Biologics License Application seeking accelerated approval for UX111 (rebisufligene etisparvovec) AAV9 gene therapy as a treatment for patients with Sanfilippo syndrome Type A (MPS IIIA)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526139084/rare-20260402.htm)) |
| May 5, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526206368/rare-ex99_1.htm)) |
| 2H 2026 | [Apazunersen topline data readout](https://sec-api.dev/pdufa/apazunersen) | RARE |  | scheduled | "Study completion is expected in the second half of 2026 and the Company plans to move with urgency to provide topline data and progress to regulatory submission." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000095017025100918/rare-20250731.htm)) |
| July 10, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06617429 (Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06617429)) |
| August 4, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526332802/rare-ex99_1.htm)) |
| August 23, 2026 | [Pariglasgene brecaparvovec PDUFA date](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec) | RARE | glycogen storage disease type Ia | scheduled | "The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1515673/000119312526062568/rare-20260223.htm)) |
| September 19, 2026 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | Sanfilippo syndrome type A | scheduled | "In April 2026, we announced that the FDA had accepted our resubmitted BLA seeking accelerated approval for UX111 as a treatment for patients with Sanfilippo syndrome Type A. The FDA granted the BLA Priority Review and assigned a PDUFA action date of September 19, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1515673/000119312526333233/rare-20260630.htm)) |
| October 30, 2026 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/rare-ex99_1.htm)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT06415344 (Long-term Extension of GTX-102 in Angelman Syndrome): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06415344)) |
| October 30, 2026 | [Apazunersen primary completion](https://sec-api.dev/pdufa/apazunersen) | RARE | Angelman Syndrome | withdrawn | "NCT07157254 (A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-10-30 (ACTUAL); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07157254)) |
| January 2027 | [Setrusumab primary completion](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | scheduled | "NCT06636071 (Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06636071)) |
| Jan to Apr 2027 | [Setrusumab topline data readout](https://sec-api.dev/pdufa/setrusumab) | RARE | Osteogenesis Imperfecta | scheduled | "NCT06636071 (Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06636071)) |
| August 2027 | [Adjuvant immunomodulatory (im) therapy primary completion](https://sec-api.dev/pdufa/adjuvant-immunomodulatory-im-therapy) | RARE | Mucopolysaccharidosis IIIA; MPS IIIA; Sanfilippo Syndrome | scheduled | "NCT04360265 (Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04360265)) |
| Aug to Nov 2027 | [Adjuvant immunomodulatory (im) therapy topline data readout](https://sec-api.dev/pdufa/adjuvant-immunomodulatory-im-therapy) | RARE | Mucopolysaccharidosis IIIA; MPS IIIA; Sanfilippo Syndrome | scheduled | "NCT04360265 (Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04360265)) |
| August 2027 | [Triheptanoin primary completion](https://sec-api.dev/pdufa/triheptanoin) | RARE | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | scheduled | "NCT05933200 (A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933200)) |
| Aug to Nov 2027 | [Triheptanoin topline data readout](https://sec-api.dev/pdufa/triheptanoin) | RARE | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | scheduled | "NCT05933200 (A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933200)) |
| September 2027 | [Avalotcagene ontaparvovec primary completion](https://sec-api.dev/pdufa/avalotcagene-ontaparvovec) | RARE | OTC Deficiency | scheduled | "NCT05345171 (Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05345171)) |
| Sep to Dec 2027 | [Avalotcagene ontaparvovec topline data readout](https://sec-api.dev/pdufa/avalotcagene-ontaparvovec) | RARE | OTC Deficiency | scheduled | "NCT05345171 (Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05345171)) |
| March 2029 | [FAYUVI (rebisufligene etisparvovec) primary completion](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | MPS IIIA; Sanfilippo Syndrome; Sanfilippo A | scheduled | "NCT02716246 (Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02716246)) |
| Mar to Jun 2029 | [FAYUVI (rebisufligene etisparvovec) topline data readout](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE | MPS IIIA; Sanfilippo Syndrome; Sanfilippo A | scheduled | "NCT02716246 (Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Ultragenyx Pharmaceutical Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02716246)) |

## Drugs

- [Adjuvant immunomodulatory (im) therapy](https://sec-api.dev/pdufa/adjuvant-immunomodulatory-im-therapy): Mucopolysaccharidosis IIIA
- [Apazunersen](https://sec-api.dev/pdufa/apazunersen): Angelman Syndrome
- [Avalotcagene ontaparvovec](https://sec-api.dev/pdufa/avalotcagene-ontaparvovec): OTC Deficiency
- [Bisphosphonate](https://sec-api.dev/pdufa/bisphosphonate): Osteogenesis Imperfecta
- [Pariglasgene brecaparvovec](https://sec-api.dev/pdufa/pariglasgene-brecaparvovec): glycogen storage disease type ia, aged eight years and older
- [FAYUVI (rebisufligene etisparvovec)](https://sec-api.dev/pdufa/rebisufligene-etisparvovec): sanfilippo syndrome type a, MPS IIIA
- [Setrusumab](https://sec-api.dev/pdufa/setrusumab): Osteogenesis Imperfecta
- [Triheptanoin](https://sec-api.dev/pdufa/triheptanoin): Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rare/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RARE catalysts: Ultragenyx Pharmaceutical Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rare/catalysts

```bibtex
@misc{secapidev_companies_rare_catalysts_20261116,
  title        = {RARE catalysts: Ultragenyx Pharmaceutical Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rare/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rare_catalysts_20261116","title":"RARE catalysts: Ultragenyx Pharmaceutical Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rare/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
